Theravance

Theravance Biopharma develops and commercializes innovative small molecule medicines for patients with serious illnesses. The company's core focus is on organ-selective therapeutics, employing a targeted scientific approach to minimize systemic exposure and maximize efficacy in specific tissues. This strategy aims to deliver impactful treatments, particularly in respiratory and inflammatory diseases, exemplified by its approved product, YUPELRI, a once-daily nebulized therapy.

Theravance Biopharma, Inc. was established in 2014 as an independent spin-off from Theravance, Inc., a company originally co-founded in 1996 by Dr. George Whitesides, a distinguished Harvard chemist. The foundational insight stemmed from leveraging sophisticated chemical principles for the discovery and development of novel small-molecule drug candidates. This rich scientific heritage propelled the creation of Theravance Biopharma, which, under CEO Rick E. Winningham, continues to advance its distinct pipeline of proprietary medicines.

The company primarily serves patients suffering from chronic respiratory conditions and other serious inflammatory diseases requiring precise therapeutic intervention. Theravance Biopharma envisions transforming disease treatment by persistently pursuing the discovery and development of new organ-selective medicines. Its long-term mission remains centered on delivering differentiated and meaningful solutions that significantly improve the health and lives of patients.

High-Level Overview

Theravance Biopharma, Inc. is a biopharmaceutical company headquartered in South San Francisco, CA, focused on discovering, developing, and commercializing organ-selective medicines to transform treatments for specialty respiratory and neurologic diseases.[1][2][3] It serves patients with serious conditions like chronic obstructive pulmonary disease (COPD) and symptomatic neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA), addressing unmet needs through its FDA-approved product YUPELRI® (revefenacin) for COPD maintenance and late-stage investigational drug ampreloxetine for nOH in MSA patients.[3][5] With 98 employees and $64.4M in revenue, the company reported record YUPELRI net sales and non-GAAP breakeven in Q3 2025, signaling strong growth momentum driven by financial discipline and pipeline advancement.[2][5]

Origin Story

Theravance Biopharma emerged from decades of expertise in biopharma innovation, evolving into a focused entity dedicated to organ-selective medicines for respiratory and neurologic conditions.[1][3] While specific founding details are not detailed in available sources, the company has developed key assets like YUPELRI®, FDA-approved for COPD, and advanced ampreloxetine through late-stage trials, marking pivotal moments in commercialization and clinical progress.[3][5] Its strategic anchors—insight-driven innovation, outsourcing non-core processes, integrated teams, and uncertainty management—have shaped its path to delivering "Medicines that Make a Difference®."[3]

Core Differentiators

• Organ-Selective Medicines: Targets specialty respiratory (e.g., COPD via YUPELRI®) and neurologic diseases (e.g., nOH in MSA via ampreloxetine), leveraging insight to address significant patient needs with novel mechanisms like norepinephrine reuptake inhibition.[1][3][5]
• Pipeline Strength: Internally discovered programs, including late-stage ampreloxetine showing durable symptom improvement, increased norepinephrine levels, blood pressure benefits, and no supine hypertension signals in MSA patients.[5]
• Operational Efficiency: Achieved non-GAAP breakeven with record YUPELRI sales; outsources non-core functions while fostering integrated R&D for faster development.[3][5]
• Patient Commitment: Beyond lab work, emphasizes real-world impact for patients and caregivers in serious illnesses.[1][3]

Role in the Broader Tech Landscape

Theravance rides the wave of precision medicine in biopharma, focusing on organ-selective therapies amid rising demand for targeted treatments in aging populations with chronic respiratory and neurodegenerative diseases like COPD and MSA.[1][3][5] Timing aligns with post-pandemic emphasis on respiratory health and unmet neurologic needs, bolstered by market forces such as FDA approvals and payer support for innovative inhalers and oral therapies.[3][5] By commercializing YUPELRI and advancing ampreloxetine toward potential first-in-class status, Theravance influences the ecosystem through shareholder value creation and pipeline contributions that could expand options for underserved patients.[3][5]

Quick Take & Future Outlook

Topline results from the pivotal Phase 3 CYPRESS study for ampreloxetine are expected in Q1 2026, potentially unlocking a breakthrough for MSA-nOH symptoms and driving further revenue growth beyond YUPELRI's momentum.[5] Trends like AI-accelerated drug discovery and personalized neurology will shape its trajectory, amplifying its innovation edge in a competitive biopharma landscape.[3] Theravance's disciplined approach positions it to sustain breakeven profitability while expanding its transformative impact, reinforcing its mission to deliver medicines that truly matter for serious diseases.[1][5]